BMS's anti-PD1 Opdivo takes lead in lung cancer
This article was originally published in Scrip
Bristol-Myers Squibb's lead immune-oncology product Opdivo (nivolumab) looks set to become the first PD-1 inhibitor to gain approval for a major lung cancer indication after an interim analysis of the Phase III CheckMate–017 study showed that it improved overall survival compared with the control chemotherapy arm.
You may also be interested in...
The Danish company pockets $40m as the lead asset in the potential multi-billion dollar deal with AbbVie for bi-specific antibodies progresses into Phase III, and while it looks to build up its commercial infrastructure.
Days after buying Kymab, Sanofi partners with Israel’s Biond on IO candidate targeting ILT2. Gilead again tackles functional cure of hepatitis B in alliance with Vir.
Putting aside the coronavirus pandemic for a while, and turning to industry’s more bread and butter R&D activities, Scrip takes a look at the industry’s biggest clinical trial hits and misses of the year.